Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedA new revision entry, v3.6.6, was added to the study record history, and the previous revision, v3.6.5, was removed from the current listing.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing the previous Revision: v3.6.4, indicating a site version update reflected on the page. This update appears to be a platform-level change rather than content changes to the trial record.SummaryDifference0.0%

- Check50 days agoChange DetectedDifference0.2%

- Check72 days agoChange DetectedThe latest version shows Revision: v3.6.3, replacing the previous v3.6.2. This indicates a platform update rather than changes to study content.SummaryDifference0.0%

- Check79 days agoChange DetectedThe page history now records a new revision (v3.6.2) and removes an older revision (v3.6.0), updating the version history to reflect the latest state of the page.SummaryDifference0.0%

- Check93 days agoChange DetectedNew navigation items 'Check who can join' and 'Find Contact Information' appear on the study record history. The revision label updates to Revision: v3.6.0, replacing the previous v3.5.5.SummaryDifference0.2%

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.